Equity
€3,000 from €164,335 in 2024
Equity fell by 98% in 1 year.
Endoverdi
Lifetime
4 annual accounts with figures on one time axispeak €216,685 (2025)
€216,685▲ 89.2%
peak €166,359 (2025)
€166,359▲ 81.3%
peak €164,335 (2024)
€3,000▼ 98.2%
€232,194▲ 12×
Board1 name since 2022
Documentsfilings and deeds
29-06-202632 days before the deadline
2025micro format
Gross margin from €114,508 to €216,685Result from €91,738 to €166,359Dividend €327,694Equity from €164,335 to €3,000Debts from €18,673 to €232,194Investments €1,905
Key points
from the 2025 annual accountsDebts
€232,194 99% of the balance sheet
Suppliers 1%Taxes and wages 1%Other 98%
Investments
€1,905 1.8 × depreciation
Green is investment, beige is depreciation.
Liquidity
1.00 was 9.68 in 2024
Short-term debts rose from €18,673 to €232,194.
Filings
4 annual accounts 2 late
The 2023 accounts came latest: 321 days after the end of the period.
Position in the sector
1.3%
Lower solvency than 94% of companies in human health. Sector median 63.0% · 20,760 companies.
Checked score
91
Excellent
Financially stronger than 27% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,185 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.2%
01-2025: 0.1%▼ -0.1 percentage points vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.2%▲ +0.1 percentage points vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.2%● unchanged vs 06-2025highest value
08-2025: < 0.1%▼ -0.2 percentage points vs 07-2025lowest value
09-2025: < 0.1%● unchanged vs 08-2025lowest value
10-2025: < 0.1%● unchanged vs 09-2025lowest value
11-2025: < 0.1%● unchanged vs 10-2025lowest value
12-2025: < 0.1%● unchanged vs 11-2025lowest value
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: 0.1%▲ +0.1 percentage points vs 06-2026
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
Equity €3,000 (1.3% of total assets)
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 1.00, cash €105,885
Size: total assets €235,194
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 6% of them on solvency, 20% on liquidity, 80% on profitability and 3% on growth.
The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 2,157 companies had the same profile as Endoverdi has now. Each dot stands for 6 companies, two years later.
94.1%
were still trading
2.8%
stopped another way
3.0%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of Endoverdi itself is lower: 0.1% within 12 months. It rests on far more data about Endoverdi than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,157 companies, not a prediction for Endoverdi. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 6% of 20760 sector peers (2025).
NBB · sector comparisonPosition among 20760 sector peers
Solvency
better than 6%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-06-2026, 32 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
32 days early
2024
23 days early
2023
321 days late
2022
22 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 4 accounts on average 72 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 31 July (3 of the last 4 accounts filed within 32 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- VERDICKT Sébastien Yves Thibault Benoit Marie 30 sharesdeed of 05-10-2022
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0791788630
Incorporation
Founding capital of €3,000, 30 shares · Founder: VERDICKT Sébastien Yves Thibault Benoit Marie · Appointment: VERDICKT Sébastien Yves Thibault Benoit Marie (director) · published on 05-10-2022 · Gazette deed
First establishment
Bruinbeekstraat 22, Bonheiden
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Endoverdi Schaerbeek | €235,194 | €216,685 | 1.3% | - |
| AZGAS MEDICAL Woluwe-Saint-Lambert | €242,733 | €196,430 | 73.6% | - |
| DOCTEUR BERTRAND KAIRIS Liège | €230,865 | €211,660 | 10.6% | - |
| Dr. Guido Claessen, Cardioloog Hasselt | €221,432 | €219,631 | 71.7% | - |
| Dokter P. Windal, anesthesist Grimbergen | €251,084 | €211,625 | 28.5% | - |
| Dr. Nelson Korir Anesthesie Wommelgem | €257,837 | €222,648 | 100.0% | - |
| MORFEI MEDICAL Namur | €217,984 | €199,793 | 1.1% | - |
These companies have the same main activity as Endoverdi: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €218,000 and €258,000, founded between 2022 and 2023.
Official details
Source: KBO- Status
- Active since 03-10-2022Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.337.019.0202820 Bonheiden, since 03-10-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 30-10-2024
Annual accounts 2025
- ≈ €400,000estimated
- €235,194▲ 28.5%
- Filing
- Filed on 29-06-2026, 32 days before the end of the filing period
Insights on Endoverdi
Endoverdi files the micro format. That format states no turnover. The gross margin rose from €13,651 in 2022 to €216,685 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Endoverdi
- What is the company number of Endoverdi?
- The company number of Endoverdi is 0791.788.630. The VAT number is the same number with BE in front: BE 0791.788.630.
- Where is Endoverdi based?
- The registered office is at Emile Maxlaan 162, 1030 Schaerbeek.Company details
- What does Endoverdi do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of Endoverdi?
- Endoverdi is a private limited company (BV).
- When was Endoverdi founded?
- Endoverdi was founded on 03-10-2022.
- Is Endoverdi still active?
- Yes, Endoverdi is an active enterprise in the KBO register.
- What is the turnover of Endoverdi?
- The turnover in financial year 2025 is ≈ €400,000. This figure is estimated from the gross margin of €216,685 and 41 comparable companies (NACE 86220). It probably lies between €340,000 and €540,000.Financials
- Is Endoverdi profitable?
- In financial year 2025, Endoverdi made a profit of €166,359.
- Where can I find the annual accounts of Endoverdi?
- Endoverdi filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Endoverdi due?
- Endoverdi must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.